Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioInvent has dosed first patient in a multicenter, randomized, double-blind, placebo-controlled Phase II study evaluating BI-204 in patients with stable atherosclerotic cardiovascular disease.
Subscribe to our email newsletter
The company expects to recruit around 120 patients at approximately 20 centers in the US and Canada.
The study is designed to demonstrate a reduction in plaque inflammation following treatment as quantified by FDG-PET imaging (18F 2-deoxyglucose positron emission tomography).
BioInvent said the antibody has been developed in collaboration with Genentech, a member of the Roche Group.
BioInvent CEO Svein Mathisen said the results from this phase II clinical trial will provide further insights into BI-204’s ability to reduce plaque inflammation and how it potentially can add to current treatment of coronary heart disease.